Recombinant Vaccines Market to reach USD 32.83 Billion by 2032, and grow at a CAGR of 11.88%.
The driving force behind the substantial growth of the recombinant vaccine market is the increasing prevalence of infectious diseases on a global scale. As a result, vaccinations have become a highly important practice across the globe. Governmental initiatives also fuel this trend. Specifically, as reported by WHO, over 2.5 million deaths were associated with vaccine-preventable diseases in 2023. In the U.S., the rate of vaccination as reported by the CDC showed a 12 percent increase, or approximately 20.3 million additional vaccinations delivered. The effect was particularly pronounced in the cases of hepatitis B and HPV, which represent contagions addressed by recombinant vaccines.